Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Can Fite Biopharma Ltd ADR is a biotechnology business based in the US. Can Fite Biopharma Ltd ADR shares (CANF) are listed on the NYSE MKT and all prices are listed in US Dollars. Can Fite Biopharma Ltd ADR employs 8 staff and has a trailing 12-month revenue of around $864,000.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $0.76 |
|---|---|
| 52-week range | $0.74 - $2.60 |
| 50-day moving average | $0.87 |
| 200-day moving average | $1.02 |
| Wall St. target price | $6.08 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.75 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.76 from 2022-09-26
| 1 week (2022-09-20) | -7.32% |
|---|---|
| 1 month (2022-08-26) | -20.83% |
| 3 months (2022-06-28) | -13.64% |
| 6 months (2022-03-28) | -33.91% |
| 1 year (2021-09-28) | -55.03% |
|---|---|
| 2 years (2020-09-28) | -55.81% |
| 3 years (2019-09-27) | 2.11 |
| 5 years (2017-09-27) | 1.7215 |
| Revenue TTM | $864,000 |
|---|---|
| Gross profit TTM | $853,000 |
| Return on assets TTM | -61.3% |
| Return on equity TTM | -175.39% |
| Profit margin | 0% |
| Book value | $0.36 |
| Market capitalisation | $20.7 million |
TTM: trailing 12 months
We're not expecting Can Fite Biopharma Ltd ADR to pay a dividend over the next 12 months.
Can Fite Biopharma Ltd ADR's shares were split on a 1:15 basis on 9 May 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can Fite Biopharma Ltd ADR shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Can Fite Biopharma Ltd ADR shares which in turn could have impacted Can Fite Biopharma Ltd ADR's share price.
Over the last 12 months, Can Fite Biopharma Ltd ADR's shares have ranged in value from as little as $0.74 up to $2.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can Fite Biopharma Ltd ADR's is 1.5949. This would suggest that Can Fite Biopharma Ltd ADR's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.